Industry-sponsored satellite symposia are educational, and some offer CME credit. This program is not a part of the official ACEP18 education program as planned by ACEP’s educational meetings committee.

Is That IV Necessary? Advances in Pain Management in the ED
Grantor: Acelrx Pharmaceuticals, Inc.
6–8 a.m. (registration, breakfast, and program)
Grand Hall A, Lobby, Manchester Grand Hyatt

Pain is the most common reason people visit the emergency department. IV opioids such as morphine and fentanyl have long been the mainstay of treatment for moderate-to-severe acute pain; however, IV drug administration can require significant ED resources (bed, nurse, equipment, etc.). During busy periods, these resources may be limited, thereby presenting a significant barrier to timely pain relief for patients. Novel classes of analgesics have recently been introduced and could offer potential advantages in settings where immediate IV access may be difficult. Join our experts, James Miner, MD, and Zubaid Rafique, MD, as they review the evolving landscape of emergency medicine acute pain management. Clinical trial-derived efficacy, safety, and pharmacokinetic data will be briefly discussed, with attention given to adverse events, their identification and management strategies. This educational opportunity features case-based presentations with an interactive Q&A session intended to maximize attendee learning.

A Virtual Reality View—Optimizing Immuno-Oncology Therapy Through the Management of Immune-Related Adverse Events: The Role of Emergency Physicians
Grantors: Bristol-Myers Squibb and Merck & Co.
6–8 a.m. (registration, breakfast, and program)
San Diego Ballroom Lobby, Marriott Marquis

Among the standard approaches to cancer treatment, including surgery, radiation, chemotherapy, and targeted therapy, immunotherapy has emerged as a different, promising modality to fight cancer. Among immunotherapies, a new class of agents called immune checkpoint inhibitors have revolutionized the approach to many advanced malignancies. Unlike chemotherapy, these agents do not directly attack cancer cells, but block key negative regulators of the immune system and reactivate its ability to attack and fight the tumor. The most important immune regulators are cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1), and its ligand PD-L1. Often tumors exploit the immune checkpoints during T-cell priming or T-cell activation in the tumor microenvironment. Several immunotherapeutic agents are now U.S. Food and Drug Administration approved, with several more in clinical trials. A new spectrum of inflammatory toxicities, called immune-related adverse events (IRAEs), has emerged, unique to the immune checkpoint blockade, that potentially affects any organ system.
Given the rapid increase in the use of these agents, emergency physicians must become familiar with immune checkpoint inhibitors, able to recognize associated IRAEs, and up to date with new guidelines on their management by a multidisciplinary team. Join our cancer expert, Arjun Balar, MD, as he reviews the evolving landscape of cancer immunotherapy and the crucial importance of recognition and management of IRAEs. Clinical efficacy and safety data across tumor types will be discussed, with special attention to the different types and severity of IRAEs and identification and management strategies. This CME activity features an interactive case-based presentation, including virtual reality animations, followed by a Q&A session that encourages attendees to maximize their learnings as they apply to clinical practice.